Insights

Insights From Our Experts

Articles

The End of the Traditional Launch: How JCA, HTA Evolution and Pricing Pressures Are Driving Continuous Evidence Generation

In a recent article published by Pharmaceutical Commerce, EVERSANA’s Chris Cameron and Tim Reason explore how evolving health technology assessment (HTA) requirements, Joint Clinical Assessment (JCA) implementation and increasing pricing pressures are reshaping the commercialization landscape…

ESMO 2026: What Did We Learn?

From AI-enabled decision tools to the continued evolution of precision oncology, ESMO 2026 offered a look at the innovations shaping the next era of cancer care. EVERSANA oncology leaders Anne Marie Robertson, Executive Vice President, and…

Let AI Prepare. Let People Decide.

Which pharmacovigilance (PV) decisions still need a qualified human behind them?  AI can help reduce the reading, triage, and transcription surrounding safety decisions, but accountability still sits with people.  As regulatory guidance increasingly emphasizes human oversight,…

HEOR Studio: Building Evidence for an AI-enabled Commercialization Ecosystem

“The future of HEOR is not about producing more analyses. It is about creating a better system for generating, maintaining, and applying evidence.”  A More Connected Model for HEOR  HEOR has traditionally been organized around discrete…

The Rise of the Sequencing Strategist

Why oncology marketers must think beyond the brand “The product hasn’t changed. But the market it was built for has.” Barry Vucsko, SVP, Strategic Development, EVERSANA INTOUCH In oncology, a brand’s biggest threat may not be…

The Future of HEOR: Moving Beyond Static Deliverables

“The next era of HEOR will not be defined by static evidence deliverables. It will be defined by continuously learning evidence engines that keep pace with an increasingly dynamic healthcare environment.” A Profession at an Inflection…

From Evidence Generation to Evidence Ecosystems: Why Integrated RWE Is Becoming a Strategic Advantage

More data does not automatically create better evidence. Pharmaceutical manufacturers have access to more healthcare data than ever, yet fragmented evidence generation can still leave critical questions unanswered.  When Real-World Evidence (RWE), Health Economics and Outcomes…

Navigating the Maze: Strategies for Emerging & Established Biopharmas to Successfully Launch in Europe

Europe remains one of the most important pharmaceutical markets in the world, but successfully launching a therapy across the region has never been more complex. In a recent article for the European Biopharmaceutical Review (EBR) Bio-Europe…

From PICO Planning to JCA Monitoring: Building Market Access Readiness in the EU JCA Era

What has the EU Joint Clinical Assessment (JCA) taught us about PICO planning?   Two years into the EU JCA, one lesson is clear: successful market access starts long before submission.  In this white paper, NAVLIN by…

The Side Effect Nobody Reported

Why Social Media Is a Blind Spot in Pharmacovigilance, and How Life Sciences Companies Can Close the Gap Social media has become an important source of real-world patient safety information, yet many pharmacovigilance systems were designed…